Bioventus Inc (OQ:BVS)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Anthony P. Bihl
Interim Chief Executive Officer, Director
Mark Singleton
Chief Financial Officer, Senior Vice President
Katrina Church
Senior Vice President, Chief Compliance Officer
Anthony D'adamio
Senior Vice President, General Counsel
Sharon W. Klugewicz
Senior Vice President - Quality and Regulatory Affairs
Business Overview
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its Pain Treatments consist of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions consist of bone graft substitutes (BGS) to fuse and grow bones and ultrasonic medical devices used for precise bone sculpting, removal of tumors, and tissue debridement in various surgeries, including spine and neurosurgery. Its Restorative Therapies consist of an ultrasonic bone healing system for fracture care, and advanced rehabilitation devices designed to help patients regain leg or hand function due to stroke.
Financial Overview
For the nine months ended 30 September 2023, Bioventus Inc revenues decreased 2% to $376.9M. Net loss before extraordinary items increased less than 1% to $90.6M. Revenues reflect U.S. segment decrease of 5% to $331.1M. Net income reflects Impairment of assets decrease of 37% to $78.6M (expense), Selling, general ane expe decrease of 10% to $219.3M (expense).
Employees: 970 as of Sep 30, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $696.19M as of Sep 30, 2023
Annual revenue (TTM): $502.76M as of Sep 30, 2023
EBITDA (TTM): $90.95M as of Sep 30, 2023
Net annual income (TTM): -$122.57M as of Sep 30, 2023
Free cash flow (TTM): -$0.18M as of Sep 30, 2023
Net Debt Last Fiscal Year: $367.79M as of Sep 30, 2023
Shares outstanding: 78,752,567 as of Oct 27, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.